Quetiapine
- Generic Name
- Quetiapine
- Brand Names
- Seroquel
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25N3O2S
- CAS Number
- 111974-69-7
- Unique Ingredient Identifier
- BGL0JSY5SI
- Background
Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as Clozapine and Olanzapine.
- Indication
Quetiapine is used in the symptomatic treatment of schizophrenia. In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in combination with antidepressant drugs for the treatment of major depression.
Some off-label uses for this drug include the management of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and psychosis associated with Parkinson's disease.
- Associated Conditions
- Bipolar 1 Disorder, Depressive Episodes, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
Interaction Between Cocaine and Quetiapine - 1
- Conditions
- Cocaine-Related Disorders
- First Posted Date
- 2004-07-16
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 12
- Registration Number
- NCT00087750
- Locations
- 🇺🇸
Boston University Medical Center, Boston, Massachusetts, United States
Efficacy & Safety of Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia
- Conditions
- Schizophrenia
- First Posted Date
- 2004-06-18
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 535
- Registration Number
- NCT00085891
- Locations
- 🇺🇸
Research Site, Kirkland, Washington, United States
Controlled Study of the Use of Quetiapine Fumarate in the Treatment of Patients With Bipolar Depression
- Conditions
- Bipolar Disorder
- First Posted Date
- 2004-06-07
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 530
- Registration Number
- NCT00083954
- Locations
- 🇺🇸
Research Site, Seattle, Washington, United States
Efficacy and Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder
- Conditions
- Bipolar Disorder
- First Posted Date
- 2004-04-19
- Last Posted Date
- 2008-12-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 710
- Registration Number
- NCT00081380
- Locations
- 🇨🇦
Research Site, Quebec, Canada
Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
- Conditions
- SchizophreniaSchizoaffective Disorder
- First Posted Date
- 2003-06-05
- Last Posted Date
- 2012-02-07
- Target Recruit Count
- 225
- Registration Number
- NCT00061802
Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression
- Conditions
- Bipolar DisorderDepression, Bipolar
- First Posted Date
- 2003-05-08
- Last Posted Date
- 2011-01-26
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00060489
Treatment and Outcome of Early Onset Bipolar Disorder
- Conditions
- Bipolar Disorder
- First Posted Date
- 2002-11-13
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 40
- Registration Number
- NCT00048802
- Locations
- 🇺🇸
The Zucker Hillside Hospital, Long Island Jewish Medical Center, Glen Oaks, New York, United States
Switching Medication to Treat Schizophrenia
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2002-09-05
- Last Posted Date
- 2016-04-28
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 219
- Registration Number
- NCT00044655
Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP)
- Conditions
- DementiaParkinson Disease
- First Posted Date
- 2002-08-15
- Last Posted Date
- 2009-12-11
- Lead Sponsor
- National Institute on Aging (NIA)
- Target Recruit Count
- 60
- Registration Number
- NCT00043849
- Locations
- 🇺🇸
Fletcher Allan Health Care, Inc., Burlington, Vermont, United States
🇺🇸Memory Clinic at Southwestern Vermont Medical Center, Bennington, Vermont, United States
🇺🇸University of Pittsburgh, Alzheimer's Disease Research Center, Pittsburgh, Pennsylvania, United States
A Comparison of Seroquel vs. Risperidone in Schizophrenia
- Conditions
- Schizophrenia
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00034905
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.